Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04606602 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)
A Phase 1 study of Dyslipidemias and Hyperlipidemias, sponsored by Silence Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 8
- Study locations
NCT04606602: Completed Phase 1 study of Dyslipidemias and Hyperlipidemias, sponsored by Silence Therapeutics.
NCT04606602 is a Phase 1 study of Dyslipidemias and Hyperlipidemias that has completed, run by Silence Therapeutics. The registered enrollment target is 70 participants, below the 230-participant average among 28 other Dyslipidemias trials with a reported enrollment target (70% lower). The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04606602, a Phase 1 study of Dyslipidemias and Hyperlipidemias, has completed, sponsored by Silence Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 8
- Study locations
Study Summary
This study will investigate the safety and tolerability of SLN360 in patients with elevated Lp(a).
Primary Outcome
safety and tolerability will be reported separately following single-dose administration.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SLN360
Study Locations (8)
Other
- Monash Medical Centre - Clayton
- Amsterdam Medical Centre - Amsterdam
- Hammersmith Medicines Research - London
Florida
- Jacksonville Center for Clinical Research Ltd. - Jacksonville
- Progressive Medical Research - Port Orange
Ohio
- Metabolic and Atherosclerosis Research Center - Cincinnati
- Cleveland Clinic - Cleveland
Western Australia
- Linear Clinical Research - Perth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2020-11-18 |
| Est. Completion | 2023-08-23 |
| Phase | Phase 1 |
What the finished NCT04606602 record still lists
NCT04606602 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 230-participant average among 28 other Dyslipidemias trials with a reported enrollment target (70% lower).
The record links to 3 conditions, with Dyslipidemias appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04606602 lists 8 locations in 4 states (Other, Florida, Ohio).
Frequently Asked Questions
What is clinical trial NCT04606602 about?
NCT04606602 is a clinical study titled "Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)". This study will investigate the safety and tolerability of SLN360 in patients with elevated Lp(a).
What is the current status of trial NCT04606602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2020-11-18. Estimated completion is 2023-08-23.
What conditions does trial NCT04606602 study?
This clinical trial studies the following conditions: Dyslipidemias, Hyperlipidemias, Elevated Lp(a).
What interventions are being tested in trial NCT04606602?
The interventions under investigation include: Placebo (DRUG), SLN360 (DRUG).
Who is sponsoring clinical trial NCT04606602?
This trial is sponsored by Silence Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04606602 being conducted?
This trial has 8 study locations across Florida, Ohio, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04606602's enrollment target sits among peer trials
70 19th of 28 higher than 10 of 28 other Dyslipidemias trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dyslipidemias trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
COMPLETED · Phase 1
-
A Study of LY3475766 in Healthy Participants
COMPLETED · Phase 1
-
Dose Response Effects of Pecan Consumption
RECRUITING · NA
-
Cottonseed Oil Dose Response
RECRUITING · NA
-
'Ai Pono Cooking Demonstrations
RECRUITING · NA
-
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI